Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Volatile element evolution of chondrules through time.

Mahan B, Moynier F, Siebert J, Gueguen B, Agranier A, Pringle EA, Bollard J, Connelly JN, Bizzarro M.

Proc Natl Acad Sci U S A. 2018 Aug 21;115(34):8547-8552. doi: 10.1073/pnas.1807263115. Epub 2018 Aug 6.

2.

Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells.

Bollard J, Patte C, Massoma P, Goddard I, Gadot N, Benslama N, Hervieu V, Ferraro-Peyret C, Cordier-Bussat M, Scoazec JY, Roche C, Walter T, Vercherat C.

Mol Cancer Ther. 2018 Jan;17(1):60-72. doi: 10.1158/1535-7163.MCT-17-0325. Epub 2017 Oct 19.

3.

Early formation of planetary building blocks inferred from Pb isotopic ages of chondrules.

Bollard J, Connelly JN, Whitehouse MJ, Pringle EA, Bonal L, Jørgensen JK, Nordlund Å, Moynier F, Bizzarro M.

Sci Adv. 2017 Aug 9;3(8):e1700407. doi: 10.1126/sciadv.1700407. eCollection 2017 Aug.

4.

mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines.

Freis P, Bollard J, Lebeau J, Massoma P, Fauvre J, Vercherat C, Walter T, Manié S, Roche C, Scoazec JY, Ferraro-Peyret C.

Oncotarget. 2017 Mar 28;8(13):20974-20987. doi: 10.18632/oncotarget.15469.

5.

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A.

Gut. 2017 Jul;66(7):1286-1296. doi: 10.1136/gutjnl-2016-312268. Epub 2016 Nov 14.

6.

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI.

Cancer Cell. 2016 Sep 12;30(3):501-503. doi: 10.1016/j.ccell.2016.08.008. Epub 2016 Sep 12. No abstract available.

7.

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI.

Cancer Cell. 2016 Sep 12;30(3):485-498. doi: 10.1016/j.ccell.2016.06.024. Epub 2016 Aug 11. Erratum in: Cancer Cell. 2016 Sep 12;30(3):501-503.

8.

Pb-Pb dating of individual chondrules from the CBa chondrite Gujba: Assessment of the impact plume formation model.

Bollard J, Connelly JN, Bizzarro M.

Meteorit Planet Sci. 2015 Jul 16;50(7):1197-1216.

9.

Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors.

Benslama N, Bollard J, Vercherat C, Massoma P, Roche C, Hervieu V, Peron J, Lombard-Bohas C, Scoazec JY, Walter T.

Invest New Drugs. 2016 Oct;34(5):654-62. doi: 10.1007/s10637-016-0363-6. Epub 2016 May 26.

PMID:
27230034
10.

The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors.

Bollard J, Massoma P, Vercherat C, Blanc M, Lepinasse F, Gadot N, Couderc C, Poncet G, Walter T, Joly MO, Hervieu V, Scoazec JY, Roche C.

Oncotarget. 2015 Nov 3;6(34):36731-45. doi: 10.18632/oncotarget.5481.

11.

Mechanisms of local invasion in enteroendocrine tumors: identification of novel candidate cytoskeleton-associated proteins in an experimental mouse model by a proteomic approach and validation in human tumors.

Couderc C, Bollard J, Couté Y, Massoma P, Poncet G, Lepinasse F, Hervieu V, Gadot N, Sanchez JC, Scoazec JY, Diaz JJ, Roche C.

Mol Cell Endocrinol. 2015 Jan 5;399:154-63. doi: 10.1016/j.mce.2014.09.006. Epub 2014 Sep 16.

PMID:
25224486
12.

Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.

Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, Gouysse G, Ferraro-Peyret C, Benslama N, Walter T, Scoazec JY, Roche C.

Neuroendocrinology. 2013;97(4):331-40. doi: 10.1159/000347063. Epub 2013 May 22.

13.

Preservation of mucus in situ in rat colon.

Bollard JE, Vanderwee MA, Smith GW, Tasman-Jones C, Gavin JB, Lee SP.

Dig Dis Sci. 1986 Dec;31(12):1338-44.

PMID:
3542443
14.

Location of bacteria in the mid-colon of the rat.

Bollard JE, Vanderwee MA, Smith GW, Tasman-Jones C, Gavin JB, Lee SP.

Appl Environ Microbiol. 1986 Mar;51(3):604-8.

15.

A 2-year follow-up of bedwetters treated by dry-bed training and standard conditioning.

Bollard J.

Behav Res Ther. 1982;20(6):571-80. No abstract available.

PMID:
7159353
16.

A component analysis of dry-bed training for treatment for bedwetting.

Bollard J, Nettelbeck T.

Behav Res Ther. 1982;20(4):383-90. No abstract available.

PMID:
7126120
17.

Dry-bed training for childhood bedwetting: a comparison of group with individually administered parent instruction.

Bollard J, Nettelbeck T, Roxbee L.

Behav Res Ther. 1982;20(3):209-17. No abstract available.

PMID:
7092764
18.

A comparison of dry-bed training and standard urine-alarm conditioning treatment of childhood bedwetting.

Bollard J, Nettelbeck T.

Behav Res Ther. 1981;19(3):215-26. No abstract available.

PMID:
7295257

Supplemental Content

Loading ...
Support Center